MOUNJARO is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
1. Treatment of postmenopausal women with osteoporosis at high risk for fracture (defined as having a history of osteoporotic fracture or multiple risk factors for fracture) or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, FORTEO reduces the risk of vertebral and nonvertebral fractures.
2. To increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy.
3. For the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy.
COSENTYX is indicated for the treatment of:
1. Plaque Psoriasis (PsO): Moderate to severe in patients aged ≥6 years who are candidates for systemic therapy or phototherapy.
2. Psoriatic Arthritis (PsA): Active, in patients aged ≥2 years.
3. Ankylosing Spondylitis (AS): Active, in adults.
4. Non-radiographic Axial Spondyloarthritis (nr-axSpA): Active, with objective signs of inflammation in adults.
5. Enthesitis-Related Arthritis (ERA): Active, in pediatric patients aged ≥4 years.
6. Hidradenitis Suppurativa (HS): Moderate to severe, in adults.
1. Acromegaly: To reduce elevated levels of growth hormone (GH) and insulin-like growth factor-1 (IGF-1) in patients who are unresponsive to or ineligible for surgical resection, pituitary irradiation, or bromocriptine mesylate.
2. Metastatic Carcinoid Tumors: For symptomatic treatment of severe diarrhea and flushing episodes.
3. Vasoactive Intestinal Peptide Tumors (VIPomas): For the management of profuse watery diarrhea associated with VIP-secreting tumors.
ORENCIA is indicated for the treatment of: Adults with moderately to severely active rheumatoid arthritis (RA);Pediatric patients ≥2 years of age with moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA);Adults and pediatric patients ≥2 years of age with active psoriatic arthritis (PsA);Prophylaxis of acute graft-versus-host disease (aGVHD) in patients ≥2 years undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1-allele mismatched unrelated donor, in combination with a calcineurin inhibitor and methotrexate.
MOUNJARO is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
1. Treatment of postmenopausal women with osteoporosis at high risk for fracture (defined as having a history of osteoporotic fracture or multiple risk factors for fracture) or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, FORTEO reduces the risk of vertebral and nonvertebral fractures.
2. To increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy.
3. For the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy.
COSENTYX is indicated for the treatment of:
1. Plaque Psoriasis (PsO): Moderate to severe in patients aged ≥6 years who are candidates for systemic therapy or phototherapy.
2. Psoriatic Arthritis (PsA): Active, in patients aged ≥2 years.
3. Ankylosing Spondylitis (AS): Active, in adults.
4. Non-radiographic Axial Spondyloarthritis (nr-axSpA): Active, with objective signs of inflammation in adults.
5. Enthesitis-Related Arthritis (ERA): Active, in pediatric patients aged ≥4 years.
6. Hidradenitis Suppurativa (HS): Moderate to severe, in adults.
1. Acromegaly: To reduce elevated levels of growth hormone (GH) and insulin-like growth factor-1 (IGF-1) in patients who are unresponsive to or ineligible for surgical resection, pituitary irradiation, or bromocriptine mesylate.
2. Metastatic Carcinoid Tumors: For symptomatic treatment of severe diarrhea and flushing episodes.
3. Vasoactive Intestinal Peptide Tumors (VIPomas): For the management of profuse watery diarrhea associated with VIP-secreting tumors.
ORENCIA is indicated for the treatment of: Adults with moderately to severely active rheumatoid arthritis (RA);Pediatric patients ≥2 years of age with moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA);Adults and pediatric patients ≥2 years of age with active psoriatic arthritis (PsA);Prophylaxis of acute graft-versus-host disease (aGVHD) in patients ≥2 years undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1-allele mismatched unrelated donor, in combination with a calcineurin inhibitor and methotrexate.
Palliative treatment of multiple myeloma;Palliative treatment of non-resectable epithelial carcinoma of the ovary.
- Nemluvio: Precautions, Dosage, Side Effects, Instructions Nemluvio (generic name: nemolizumab-ilto) is a recently approved medication designed to treat prurigo nodularis, a chronic skin condition that results in raised, itchy bumps on the skin.
506
2025-05-21 17:46:14 - Nemluvio: Safety Warnings, Dosage Guidelines, Side Effects Nemluvio (nemolizumab-ilto) is a breakthrough medication recently approved for the treatment of prurigo nodularis in adults. 508
2025-05-20 15:44:29
- Nemluvio: Treatment Uses, Proper Dosage, Possible Side Effects Nemluvio (nemolizumab-ilto) is a recently FDA-approved medication that offers relief for adults suffering from prurigo nodularis, a chronic skin disorder characterized by intense itching and the formation of raised, thickened nodules. 501
2025-04-02 14:49:52
- Nemluvio: Indications, Dosage Instructions, Side Effects Nemluvio (generic name: nemolizumab-ilto) is a newly approved medication that provides an innovative approach to managing prurigo nodularis, a chronic skin condition that causes intense itching and the formation of raised nodules. 504
2025-04-02 14:45:32
- Nemluvio: Uses, Dosage, Side Effects, and Administration Guidelines Nemluvio (generic name: nemolizumab-ilto) is an innovative biologic medication recently approved by the U.S. Food and Drug Administration (FDA) in 2024. 503
2025-04-02 14:09:13
- Nemluvio: Treatment Benefits, Dosage Recommendations, Adverse Effects Nemluvio (nemolizumab-ilto) is a newly approved medication that offers significant promise for the treatment of prurigo nodularis, a chronic and often debilitating skin condition. 501
2025-04-02 14:04:38
- Nemluvio: Clinical Uses, Recommended Dosage, Potential Side Effects Nemluvio (nemolizumab-ilto) is a recently approved biologic treatment that is making waves in the dermatology community. 500
2025-04-02 13:45:16
- Nemluvio: Uses, Dosage, Side Effects, Instructions Nemluvio is an IL-31 receptor antagonist, which means it blocks the IL-31 receptor, a key player in triggering the itch response. 502
2025-04-01 16:58:16
